Cancer - Brain

A new anti-epileptic-drug, called perampanel shows promise for being able to control and prevent seizures in patients with brain tumours. There are two separate studies in this project for patients with gliomas, a type of brain tumour.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 2)

The research is being done to test whether the active study drug, sotagliflozin, is safe in patients who have diabetes, kidney disease and who are at risk for cardiovascular events such as heart attack and stroke.

Anticipated date that enrolment will close: June 2019

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 1)

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits.

Anticipated date enrolment will close: March 2019

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

A comparative study of the safety and effectiveness of a new drug (PRN1008) as a treatment for PV and PF when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Neurological Conditions (Other) - MND, Spinal Cord Injury, Stroke

An early feasibility study of the safety of the Stentrode™ device in participants with loss of motor function due to paralysis from spinal cord injury, motor neuron disease, stroke, muscular dystrophy or loss of limbs.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cardiac Related Conditions

There are over one million heart operations performed each year. After surgery, many patients report problems with concentration, focus and memory and this can last for 3 months or longer.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Parkinsons's disease

Parkinson’s disease is a progressive neurologic disorder that mainly produces abnormal limb movements (motor system). Current treatments for Parkinson’s disease help reduce the disability of the abnormal movements, but do not slow or stop the underlying loss of brain cells (neurodegeneration).

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4